37182-75-5

Usage

Uses

Used in Environmental Applications:
1-(3-Carboxyphenyl)-2-thiourea is used as a ligand for the solid phase extraction of Hg(II) in environmental samples. The expression is: 1-(3-CARBOXYPHENYL)-2-THIOUREA is used as a ligand for [solid phase extraction of Hg(II)] for [effectively removing and detecting mercury ions in environmental samples].
Used in Analytical Chemistry:
In the field of analytical chemistry, 1-(3-Carboxyphenyl)-2-thiourea is used as a chelating agent for the selective detection and quantification of mercury ions. The expression is: 1-(3-CARBOXYPHENYL)-2-THIOUREA is used as a chelating agent for [selective detection and quantification of mercury ions] for [improving the accuracy and sensitivity of mercury analysis in various samples].
Used in Material Science:
1-(3-Carboxyphenyl)-2-thiourea functionalized mesoporous silica SBA-15 (CPTU-SBA-15) is utilized in material science for the development of novel adsorbent materials. The expression is: 1-(3-CARBOXYPHENYL)-2-THIOUREA is used as a functionalizing agent for [mesoporous silica SBA-15] for [enhancing the adsorption capacity and selectivity for mercury ions].

InChI:InChI=1/C8H8N2O2S/c9-8(13)10-6-3-1-2-5(4-6)7(11)12/h1-4H,(H,11,12)(H3,9,10,13)/p-1

Upstream product

• 433704-66-6 3-(3-benzoylthioureido)benzoic acid 
• 183430-27-5 3-cyanoamino-benzoic acid 
• 2131-63-7 3-isothiocyanatobenzoic acid 
• 99-05-8 meta-aminobenzoic acid 
• 192948-00-8 methyl 3-thioureidobenzoate 
• 1147550-11-5 ammonium thiocyanate 
• 333-20-0 potassium thioacyanate 

Downstream Products

• 183430-27-5 3-cyanoamino-benzoic acid 
• 71224-95-8 2-aminobenzo[d]thiazole-7-carboxylic acid 
• 315706-17-3 C₁₆H₁₁ClN₂O₂S 

Relevant academic research and scientific papers

ALPHA-5 BETA-1 INHIBITORS

The disclosure provides, inter alia, alpha-5 beta-1 inhibitors, pharmaceutical compositions comprising alpha-5 beta-1 inhibitors, methods for treating diseases using alpha-5 beta-1 inhibitors, and processes for making alpha-5 beta-1 inhibitors.

INHIBITORS OF GLUCOSE TRANSPORTERS (GLUTS)

The present invention relates to 2,6-methanobenzo[g][1]oxacin-4-onecompounds and their analog compounds and pharmaceutically acceptable salts thereof as selective inhibitor of glucose transporters 1 and 3 (GLUTs 1 and 3), to methods of preparing said compounds, and to the use thereof as pharmaceutically active agents, especially for the prophylaxis and/or treatment of metabolic diseases, immunological diseases, autoimmune diseases, inflammation, graft versus host disease, cancer, and metastasis thereof. Furthermore, the present invention is directed to pharmaceutical composition comprising at least one of 2,6-methanobenzo[g][1]oxacin-4-one compounds and their analog compounds.

2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 2. Structure-Based Optimization and Investigation of Effects Specific to the Allosteric Mode of Action

Protein CK2 has gained much interest as an anticancer drug target in the past decade. We had previously described the identification of a new allosteric site on the catalytic α-subunit, along with first small molecule ligands based on the 4-(4-phenylthiazol-2-ylamino)benzoic acid scaffold. In the present work, structure optimizations guided by a binding model led to the identification of the lead compound 2-hydroxy-4-((4-(naphthalen-2-yl)thiazol-2-yl)amino)benzoic acid (27), showing a submicromolar potency against purified CK2α (IC50 = 0.6 μM). Furthermore, 27 induced apoptosis and cell death in 786-O renal cell carcinoma cells (EC50 = 5 μM) and inhibited STAT3 activation even more potently than the ATP-competitive drug candidate CX-4945 (EC50 of 1.6 μM vs 5.3 μM). Notably, the potencies of our allosteric ligands to inhibit CK2 varied depending on the individual substrate. Altogether, the novel allosteric pocket was proved a druggable site, offering an excellent perspective to develop efficient and selective allosteric CK2 inhibitors.

Thiazole aminobenzoic acid derivatives and use thereof (by machine translation)

The invention discloses a have anti-tumor activity of the thiazole aminobenzoic acid derivative, it can be used for the preparation of anticancer drugs, in particular as Bcr - Abl tyrosine kinase inhibitors, in particular can be used as a T315I mutant Bcr

Thiazole aminobenzamide acetic acid derivative and application thereof

The invention discloses a thiazole aminobenzamide acetic acid derivative with anti-tumour activity, and the thiazole aminobenzamide acetic acid derivative can be used for preparing an anti-cancer drug, especially can be used as a Bcr-Abl tyrosine kinase i

Thiazol-aminobenzamide acetate derivative and application thereof

The invention discloses a thiazol-aminobenzamide acetate derivative with anti-tumor activity. The thiazol-aminobenzamide acetate derivative with the anti-tumor activity can be applied to preparing anti-cancer drugs and is particularly applicable to serving as a Bcr-Abl tyrosine kinase inhibitor, especially as a Bcr-Abl tyrosine kinase inhibitor for T3151 mutation.

Design, synthesis and broad-spectrum Bcr-Abl inhibitory activity of novel thiazolamide-benzamide derivatives

Bcr-Abl plays an important role in the pathogenesis and development of chronic myeloid leukemia (CML). But Bcr-Abl is prone to mutation, so it increases the difficulty of clinical treatment. Therefore, it is crucial to design a new class of broad-spectrum Bcr-Abl inhibitors. Herein, forty novel thiazolamide-benzamide derivatives were synthesized and evaluated their broad-spectrum Bcr-Abl inhibitory activities. The newly synthesized compounds were characterized by using spectrum data (1H NMR, APCI-MS and IR) and elemental analysis. The protein kinase results indicated that eight compounds (3a, 3e, 3m, 3n, 3p, 4c, 4f, 4g) showed high activities to wild-type and T315I mutation. The most potent compound 3m exhibited an Abl IC50 value as low as 1.273 μM and showed inhibition to the T315I mutant with IC50 value 39.89 μM. 3m could prove to be a new promising lead compound for the further development of broad-spectrum Bcr-Abl inhibitors to overcome clinical acquired resistance.

Multitarget CFTR Modulators Endowed with Multiple Beneficial Side Effects for Cystic Fibrosis Patients: Toward a Simplified Therapeutic Approach ?

Cystic fibrosis (CF) is a multiorgan disease caused by mutations of the cystic fibrosis transmembrane conductance regulator (CFTR). In addition to respiratory impairment due to mucus accumulation, viruses and bacteria trigger acute pulmonary exacerbations, accelerating disease progression and mortality rate. Treatment complexity increases with patients' age, and simplifying the therapeutic regimen represents one of the key priorities in CF. We have recently reported the discovery of multitarget compounds able to "kill two birds with one stone" by targeting F508del-CFTR and PI4KIIIβ and thus acting simultaneously as CFTR correctors and broad-spectrum enterovirus (EV) inhibitors. Starting from these preliminary results, we report herein a hit-to-lead optimization and multidimensional structure-activity relationship (SAR) study that led to compound 23a. This compound showed good antiviral and F508del-CFTR correction potency, additivity/synergy with lumacaftor, and a promising in vitro absorption, distribution, metabolism, and excretion (ADME) profile. It was well tolerated in vivo with no sign of acute toxicity and histological alterations in key biodistribution organs.

Synthesis and in-vitro evaluation of 2-amino-4-arylthiazole as inhibitor of 3D polymerase against foot-and-mouth disease (FMD)

Foot-and-mouth disease (FMD) is a highly contagious vesicular disease of livestock caused by a highly variable RNA virus, foot-and-mouth disease virus (FMDV). One of the targets to suppress expansion of and to control FMD is 3D polymerase (FMDV 3Dpol). In this study, 2-amino-4-arylthiazole derivatives were synthesized and evaluated for their inhibitory activity against FMDV 3Dpol. Among them, compound 20i exhibited the most potent functional inhibition (IC50 = 0.39μM) of FMDV 3D polymerase and compound 24a (EC50=13.09 μM) showed more potent antiviral activity than ribavirin (EC50=1367 μM) and T1105 (EC50=347 μM) with IBRS-2 cells infected by the FMDV O/SKR/2010 strain.

BETA AMINO ACID DERIVATIVES AS INTEGRIN ANTAGONISTS

Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by these integrins by inhibiting or antagonizing these integrins. The novel pharmaceutical agents include those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods and intermediates useful for making the pharmaceutical agents and methods of using the pharmaceutical agents are also provided.